Next Article in Journal
Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer
Next Article in Special Issue
NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses—Therapeutic Perspectives
Previous Article in Journal
POFUT1 as a Promising Novel Biomarker of Colorectal Cancer
Previous Article in Special Issue
Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview

Systemic Therapy for Hepatocellular Carcinoma: Latest Advances

Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, 337-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan
Cancers 2018, 10(11), 412; https://doi.org/10.3390/cancers10110412
Received: 2 October 2018 / Revised: 23 October 2018 / Accepted: 25 October 2018 / Published: 30 October 2018
(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
  |  
PDF [427 KB, uploaded 30 October 2018]
  |  

Abstract

Systemic therapy for hepatocellular carcinoma (HCC) has changed drastically since the introduction of the molecular targeted agent sorafenib in 2007. Although sorafenib expanded the treatment options for extrahepatic spread (EHS) and vascular invasion, making long-term survival of patients with advanced disease achievable to a certain extent, new molecular-targeted agents are being developed as alternatives to sorafenib due to shortcomings such as its low response rate and high toxicity. Every single one of the many drugs developed during the 10-year period from 2007 to 2016 was a failure. However, during the two-year period from 2017 through 2018, four drugs—regorafenib, lenvatinib, cabozantinib, and ramucirumab—emerged successfully from clinical trials in quick succession and became available for clinical use. The efficacy of combination therapy with transcatheter arterial chemoembolization (TACE) plus sorafenib was also first demonstrated in 2018. Recently, immune checkpoint inhibitors have been applied to HCC treatment and many phase III clinical trials are ongoing, not only on monotherapy with nivolumab, pembrolizumab, and tislelizumab, but also on combination therapy with checkpoint inhibitors, programmed death-1 (PD-1) or PD-ligand 1 (PD-L1) antibody plus a molecular targeted agent (bevacizumab) or the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody, tremelimumab. These combination therapies have shown higher response rates than PD-1/PD-L1 monotherapy alone, suggesting a synergistic effect by combination therapy in early phases; therefore, further results are eagerly awaited. View Full-Text
Keywords: hepatocellular carcinoma; systemic therapy; molecular targeted therapy; immune checkpoint inhibitor hepatocellular carcinoma; systemic therapy; molecular targeted therapy; immune checkpoint inhibitor
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kudo, M. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers 2018, 10, 412.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top